BRIEF published on 10/24/2024 at 19:35, 1 year 10 months ago ABIONYX Pharma presents the results of the RACERS study ABIONYX Pharma CER-001 Brain Fog Kidney Week Neuroinflammation
PRESS RELEASE published on 10/24/2024 at 19:30, 1 year 10 months ago Informations privilégiées / Autres communiqués ABIONYX Pharma présente les résultats cliniques de l'étude RACERS sur le brouillard cérébral et l'efficacité de CER-001 au congrès annuel 2024 de l'ASN. Nouvelles données sur la neuro-inflammation et les troubles cognitifs ASN ABIONYX Pharma CER-001 Brain-fog Étude RACERS
PRESS RELEASE published on 10/24/2024 at 19:30, 1 year 10 months ago Inside Information / Other news releases ABIONYX Pharma's RACERS study on CER-001 shows positive impact on cognitive impairment in brain-fog patients, presenting new clinical results at ASN 2024 Annual Meeting. Potential treatment for neuroinflammation ABIONYX Pharma CER-001 Brain-fog Neuroinflammation RACERS Study
BRIEF published on 10/21/2024 at 20:05, 1 year 10 months ago ABIONYX Pharma reçoit un avis favorable de l'EMA pour le CER-001 ABIONYX Pharma CER-001 EMA Déficience LCAT AMM
BRIEF published on 10/21/2024 at 20:05, 1 year 10 months ago ABIONYX Pharma receives positive EMA opinion for CER-001 ABIONYX Pharma CER-001 EMA AMM LCAT Deficiency
PRESS RELEASE published on 10/21/2024 at 20:00, 1 year 10 months ago Informations privilégiées / Autres communiqués ABIONYX Pharma reçoit un avis positif de l'EMA pour le CER-001 dans la Déficience en LCAT. L'EMA admissible à la soumission de deux lots prospectifs de validation du procédé de fabrication ABIONYX Pharma CER-001 EMA LCAT Validation Du Procédé
PRESS RELEASE published on 10/21/2024 at 20:00, 1 year 10 months ago Inside Information / Other news releases ABIONYX Pharma receives positive feedback from EMA for CER-001 in LCAT Deficiency, allowing submission of data from 2 prospective process validation batches for MAA manufacturing ABIONYX Pharma CER-001 EMA LCAT Deficiency Process Validation Batches
BRIEF published on 08/22/2024 at 18:05, 2 years ago ABIONYX Pharma : Bilan du 1er semestre 2024 Chiffre D'affaires Biotechnologie Trésorerie Levée De Fonds ABIONYX Pharma
BRIEF published on 08/22/2024 at 18:05, 2 years ago ABIONYX Pharma: Review of the first half of 2024 Biotechnology Fundraising Treasury Turnover ABIONYX Pharma
PRESS RELEASE published on 08/22/2024 at 18:00, 2 years ago Informations privilégiées / Autres communiqués ABIONYX Pharma publie sa position de trésorerie du 1er semestre 2024 avec un chiffre d’affaires consolidé de 2,4 M€. Levée de fonds de 3,4 M€ pour renforcer la trésorerie Chiffre D'affaires Biotechnologie Trésorerie Levée De Fonds ABIONYX Pharma
Published on 08/28/2026 at 14:00, 4 hours 32 minutes ago Lobe Sciences Expands Leadership Team with New CFO Appointment
Published on 08/28/2026 at 13:00, 5 hours 32 minutes ago Abasca Files NI 43-101 Technical Report, Commences Summer Exploration Program at Loki and Elects to File Semi-annual Interim Financial Statements and Related MD&A
Published on 08/28/2026 at 08:05, 10 hours 27 minutes ago Caledonia Mining Corporation Plc: Maiden Mineral Resource Estimate at Motapa 379,000 oz Measured and Indicated; 131,000 oz Inferred
Published on 08/28/2026 at 08:05, 10 hours 27 minutes ago Tocvan Announces New Surface Mineralization in Several Zones at Gran Pilar Gold-Silver Project
Published on 08/28/2026 at 08:00, 10 hours 32 minutes ago Caledonia Mining Corporation Plc: Blanket Mine Underground Measured and Indicated Mineral Resources Estimate Increases by 22% to 2.18 Million Ounces and Declaration of a Surface Mineral Resource Estimate
Published on 08/28/2026 at 18:01, 30 minutes ago CPI Europe announces unaudited results for the first half of 2026
Published on 08/28/2026 at 18:00, 32 minutes ago Highlight Event and Entertainment AG publishes results for the first half of 2026
Published on 08/28/2026 at 18:00, 32 minutes ago Investis successfully issues a fixed rate bond of CHF 100 million
Published on 08/28/2026 at 18:00, 32 minutes ago Investis émet avec succès un emprunt obligataire à taux fixe d’un volume de CHF 100 millions
